CH-VAD Developer TonHe Receives FDA Conditional Approval for First-in-Class Fully Magnetically Levitated Pediatric Artificial Heart Trial

BrioHealth SolutionsBrioHealth Solutions, a wholly-owned subsidiary in the United States, announced，The company has received conditional approval from the U.S. Food and Drug Administration (FDA) to initiate BrioVA for pediatric patients with advanced heart failure.D®Systematic Clinical Evaluation. Brio4Kids TrialAsExtension of the INNOVATE Trial into the Pediatric Field，Will rely onAfterPatientInvestigational Device Exemption (IDE)This not only realized the first prospective clinical trial of a fully magnetically levitated artificial heart for pediatric use, but also marked the first time that the same left ventricular assist device (LVAD) was evaluated in parallel clinical trials in both adult and pediatric populations, filling the gap in the treatment of pediatric heart failure.